furosemide has been researched along with Overweight in 1 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This patient's case highlights the need of further studies evaluating efficacy of repeated dosing of CCP." | 1.62 | Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient. ( Bloch, EM; Chua, F; Goel, R; Katz, LM; Mirihagalle, N; Parajuli, P; Prakash, V; Saha, D; Shah, A; Sundareshan, V; Tobian, AAR; Waqar, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mirihagalle, N | 1 |
| Parajuli, P | 1 |
| Sundareshan, V | 1 |
| Saha, D | 1 |
| Shah, A | 1 |
| Chua, F | 1 |
| Waqar, S | 1 |
| Prakash, V | 1 |
| Tobian, AAR | 1 |
| Bloch, EM | 1 |
| Katz, LM | 1 |
| Goel, R | 1 |
1 other study available for furosemide and Overweight
| Article | Year |
|---|---|
Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient.
Topics: Anti-Bacterial Agents; Combined Modality Therapy; COVID-19; COVID-19 Serotherapy; Diabetes Mellitus, | 2021 |